Iain Stuart

512 total citations
24 papers, 243 citations indexed

About

Iain Stuart is a scholar working on Dermatology, Epidemiology and Cell Biology. According to data from OpenAlex, Iain Stuart has authored 24 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Dermatology, 4 papers in Epidemiology and 4 papers in Cell Biology. Recurrent topics in Iain Stuart's work include Acne and Rosacea Treatments and Effects (17 papers), Dermatology and Skin Diseases (12 papers) and Dermatologic Treatments and Research (7 papers). Iain Stuart is often cited by papers focused on Acne and Rosacea Treatments and Effects (17 papers), Dermatology and Skin Diseases (12 papers) and Dermatologic Treatments and Research (7 papers). Iain Stuart collaborates with scholars based in United States and Czechia. Iain Stuart's co-authors include Linda Stein Gold, Steven J. McClue, Leon Kircik, Herman Ellman, Jonathan Weiss, J.Q. Del Rosso, Zoé Kececioglu Draelos, Sunil Dhawan, Neal Bhatia and Walter K. Nahm and has published in prestigious journals such as Blood, Annals of the Rheumatic Diseases and Journal of Investigative Dermatology.

In The Last Decade

Iain Stuart

18 papers receiving 236 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iain Stuart United States 9 154 88 32 25 21 24 243
Jenny Dai United States 5 135 0.9× 58 0.7× 25 0.8× 24 1.0× 13 0.6× 5 303
Stanley B. Levy United States 9 114 0.7× 36 0.4× 8 0.3× 16 0.6× 3 0.1× 24 280
Qinqin Peng China 10 170 1.1× 45 0.5× 19 0.6× 47 1.9× 64 3.0× 12 268
Yan Teng China 8 79 0.5× 12 0.1× 32 1.0× 41 1.6× 5 0.2× 23 204
Claire Whitmore United States 5 306 2.0× 79 0.9× 8 0.3× 39 1.6× 10 0.5× 6 376
Chayada Chaiyabutr Thailand 9 147 1.0× 103 1.2× 11 0.3× 21 0.8× 41 262
Stéphanie Arsonnaud France 11 266 1.7× 52 0.6× 5 0.2× 50 2.0× 6 0.3× 13 296
Alan Greenspan United States 8 243 1.6× 56 0.6× 4 0.1× 56 2.2× 15 0.7× 16 303
Scott Guenthner United States 8 202 1.3× 18 0.2× 47 1.5× 75 3.0× 7 0.3× 22 317

Countries citing papers authored by Iain Stuart

Since Specialization
Citations

This map shows the geographic impact of Iain Stuart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iain Stuart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iain Stuart more than expected).

Fields of papers citing papers by Iain Stuart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iain Stuart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iain Stuart. The network helps show where Iain Stuart may publish in the future.

Co-authorship network of co-authors of Iain Stuart

This figure shows the co-authorship network connecting the top 25 collaborators of Iain Stuart. A scholar is included among the top collaborators of Iain Stuart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iain Stuart. Iain Stuart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stuart, Iain, et al.. (2024). LB1055 Preclinical studies: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo. Journal of Investigative Dermatology. 144(8). S187–S187.
2.
Stuart, Iain, et al.. (2024). LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo. Journal of Investigative Dermatology. 144(8). S188–S188.
3.
Sutcliffe, Joyce A., Robert E. McLaughlin, Guy Webster, et al.. (2020). Susceptibility of Cutibacterium acnes to topical minocycline foam. Anaerobe. 62. 102169–102169. 14 indexed citations
4.
Gold, Linda Stein, J.Q. Del Rosso, Leon Kircik, et al.. (2020). Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials. Journal of the American Academy of Dermatology. 82(5). 1166–1173. 40 indexed citations
5.
Denis-Ryan, Amandine, et al.. (2020). Decarbonisation futures: solutions, actions and benchmarks for a net zero emissions Australia. 17 indexed citations
6.
Gold, Linda Stein, J.Q. Del Rosso, Leon Kircik, et al.. (2020). Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea.. PubMed. 13(11). 44–49. 7 indexed citations
7.
Rosso, J.Q. Del, Linda Stein Gold, Leon Kircik, et al.. (2020). Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients. SKIN The Journal of Cutaneous Medicine. 4(6). s89–s89.
8.
9.
Kircik, Leon, et al.. (2020). Formulation and Profile of FMX101 4% Minocycline Topical Foam for the Treatment of Acne Vulgaris.. PubMed. 13(4). 14–21. 15 indexed citations
10.
Moore, Angela, Martin Zaiac, Tory P. Sullivan, et al.. (2019). Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study. Journal of the American Academy of Dermatology. 82(4). 832–837. 39 indexed citations
11.
Sutcliffe, Joyce A., Robert E. McLaughlin, J.Q. Del Rosso, et al.. (2019). LB1117 Assessing bacterial susceptibility of FMX101 4% topical minocycline foam. Journal of Investigative Dermatology. 139(9). B18–B18. 1 indexed citations
12.
13.
Gold, Linda Stein, et al.. (2019). An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris. SKIN The Journal of Cutaneous Medicine. 3. S1–S1. 3 indexed citations
14.
Gold, Linda Stein, Sunil Dhawan, Jonathan Weiss, et al.. (2019). Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX101 4% Minocycline Foam for Moderate-to-Severe Acne Vulgaris.. PubMed. 12(10). 16–23. 7 indexed citations
15.
16.
Gold, Linda Stein, Sunil Dhawan, Jonathan Weiss, et al.. (2018). A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies. Journal of the American Academy of Dermatology. 80(1). 168–177. 38 indexed citations
17.
Moore, Angela, Martin Zaiac, Tory P. Sullivan, et al.. (2018). FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Efficacy and Safety From a Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study. SKIN The Journal of Cutaneous Medicine. 2. S56–S56. 1 indexed citations
18.
Hajdúch, Marián, David Vydra, Petr Džubák, et al.. (2008). In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2. 68. 5645–5645. 11 indexed citations
19.
Kantarjian, Hagop M., Guillermo Garcia‐Manero, Stefan Faderl, et al.. (2007). Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).. Blood. 110(11). 884–884. 2 indexed citations
20.
McClue, Steven J. & Iain Stuart. (2007). Metabolism of the Trisubstituted Purine Cyclin-Dependent Kinase Inhibitor Seliciclib (R-Roscovitine) in Vitro and in Vivo. Drug Metabolism and Disposition. 36(3). 561–570. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jenny Dai Breakdown of academic impact, for papers by Stanley B. Levy Breakdown of academic impact, for papers by Qinqin Peng Breakdown of academic impact, for papers by Yan Teng Breakdown of academic impact, for papers by Claire Whitmore Breakdown of academic impact, for papers by Chayada Chaiyabutr Breakdown of academic impact, for papers by Stéphanie Arsonnaud Breakdown of academic impact, for papers by Alan Greenspan Breakdown of academic impact, for papers by Scott Guenthner
Rankless by CCL
2026